ArticleAJNR. American journal of neuroradiology2010
Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma.
Article in AJNR. American journal of neuroradiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06263361 (Improving Safety and Accuracy of Stereotactic Brain Biopsies in Primary Central Nervous System Lymphoma), which is not on this map. Cited by 111 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Improving Safety and Accuracy of Stereotactic Brain Biopsies in Primary Central Nervous System Lymphoma (PCNSL): Integration of Advanced MRI Patterns and Fluorescein Sodium Fluorescence
Who cites it
111 citing papers in PubMed, 2 syntheses or guidelines pooled it, 223 citations in OpenAlex.
- The Role of Pretherapeutic Diffusion-Weighted MR Imaging Derived Apparent Diffusion Coefficient in Predicting Clinical Outcomes in Immunocompetent Patients with Primary CNS Lymphoma: A Systematic Review and Meta-Analysis.Asian Pacific journal of cancer prevention : APJCP · 2022Pooled it
- The correlation between apparent diffusion coefficient and tumor cellularity in patients: a meta-analysis.PloS one · 2013Pooled it
- [18F]FDG PET-MRI provides survival biomarkers in primary central nervous system lymphoma in the elderly: an ancillary study from the BLOCAGE trial of the LOC network.European journal of nuclear medicine and molecular imaging · 2023Trial
- Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2013Trial
- Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI.Clinical cancer research : an official journal of the American Association for Cancer Research · 2012Trial
- Article
- CXCR4-targeted PET/CT with [¹⁸F]AlF-NOTA-QHY-04 in primary central nervous system lymphoma: a prospective comparison with MRI and [¹⁸F]FDG PET/CT.European journal of nuclear medicine and molecular imaging · 2026Article
- Prediction of relapsed/refractory primary central nervous system lymphoma using pre-chemotherapy ITSS grade on SWI and pre-/post-chemotherapy ADC parameters on DWI.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Multiple presentations: a single pathology, primary central nervous system lymphoma (PCNSL). A multicenter study.Journal of neuro-oncology · 2026Article
- MRI biomarkers of primary CNS lymphoma outcome after MATRix: real world performance.Frontiers in oncology · 2026Article
- Article
- Dynamic susceptibility contrast perfusion MRI helps in differentiating double-expressor from non-double-expressor subtypes in primary central nervous system lymphoma.Neuroradiology · 2025Article
- Automated Lesion and Feature Extraction Pipeline for Brain MRIs with Interpretability.Neuroinformatics · 2025Article
- Primary central nervous system lymphoma: Imaging features and differential diagnosis.The neuroradiology journal · 2024Review
- Differentiation between multifocal CNS lymphoma and glioblastoma based on MRI criteria.Discover oncology · 2024Article
- Article
- Tumor-like Lesions in Primary Angiitis of the Central Nervous System: The Role of Magnetic Resonance Imaging in Differential Diagnosis.Diagnostics (Basel, Switzerland) · 2024Review
- Improved early outcome prediction by MRI-based 3D tumor volume assessment in patients with CNS lymphomas.Neuro-oncology · 2024Article
- Standard diffusion-weighted, diffusion kurtosis and intravoxel incoherent motion in differentiating invasive placentas.Archives of gynecology and obstetrics · 2024Article
- Case report: Intravascular large B cell lymphoma mimicking acute demyelinating encephalomyelitis after SARS-CoV-2 reinfection: diagnostic value of advanced MRI techniques and the literature review with the assistance of ChatGPT.Frontiers in immunology · 2024Review
51 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
background and purposeThere is evidence that increased tumor cellular density within diagnostic specimens of primary central nervous system lymphoma (PCNSL) may have significant prognostic implications. Because cellular density may influence measurements of apparent diffusion coefficient (ADC) by using diffusion-weighted MR imaging (DWI), we hypothesized that ADC measured from contrast-enhancing regions might correlate with clinical outcome in patients with PCNSL. MATERIALS AND
methodsPCNSL tumors from 18 immunocompetent patients, treated uniformly with methotrexate-based chemotherapy, were studied with pretherapeutic DWI. Enhancing lesions were diagnosed by pathologic analysis as high-grade B-cell lymphomas. Regions of interest were placed around all enhancing lesions allowing calculation of mean, 25th percentile (ADC(25%)), and minimum ADC values. Histopathologic tumor cellularity was quantitatively measured in all patients. High and low ADC groups were stratified by the median ADC value of the cohort. The Welch t test assessed differences between groups. The Pearson correlation examined relationships between ADC measurements and tumor cellular density. Single and multivariable survival analysis was performed.
resultsWe detected significant intra- and intertumor heterogeneity in ADC measurements. An inverse correlation between cellular density and ADC measurements was observed (P < .05). ADC(25%) measurements less than the median value of 692 (low ADC group) were associated with significantly shorter progression-free and overall survival. Patients with improved clinical outcome were noted to exhibit a significant decrease in ADC measurements following high-dose methotrexate chemotherapy.
conclusionsOur study provides evidence that ADC measurements within contrast-enhancing regions of PCNSL tumors may provide noninvasive insight into clinical outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.